new N - acylhydrazone derivativesdesignedas LASSBio-294 analogues
The knowledge of transition state structure has been usedto designoseltamivir analogues
using in silico modelling(passive) were designed2ME analogues
to improve the therapeutic use(passive) are designedAnalogues of Zanamivir Zanamivir analogues
to improve the therapeutic use(passive) are designedZanamivir analogues
ResearchersdesignedPGF2 analogues
subunit composition(passive) is strongly influenced byphilanthotoxin analogues
In the search for effective , selective , and nontoxic antiviral and antitumor agents , a variety of strategies have been devisedto designnucleoside analogues
two noveldesignedanalogues
which causesto inventthe analogues
by molecular simplification(passive) designed byAnalogues
structures ... the N - terminal sideto designthe analogues
decausesanalogues
to be potent and selective for p38(passive) have been designedAnalogues
who are lookingto contributethe analogues
to be incorporated into viral nucleic acids and act as chain terminators thus inhibiting efficient viral replication(passive) are designedNucleoside analogues
to time or strong points(passive) are designedThe analogues
to investigate the effects of modification of these factors on antimicrobial activities ( Table1(passive) were designedAnalogues
in order to determine new and potential antioxidant peptides(passive) were designedAnalogues of PAGY
of 2- and 4-substituted imidazoles and imidazolines attached through a methylene bridge to either the 1- or 2-naphthalene ring system(passive) were composedThe analogues
to inhibit human acetylcholinesterase for Alzheimer 's diseasedesignedto inhibit human acetylcholinesterase for Alzheimer 's disease
to resist DPP-4 degradationdesignedto resist DPP-4 degradation
to treat Hepatitis C Virus ( HCV ) infections and potentially other diseasesdesignedto treat Hepatitis C Virus ( HCV ) infections and potentially other diseases
significantlyhave contributedsignificantly
to supraphysiological GLP-1 levelsleadto supraphysiological GLP-1 levels
to inhibit the C - terminal portion of Hsp90 , which demonstrated the ability to decrease client protein expressiondesignedto inhibit the C - terminal portion of Hsp90 , which demonstrated the ability to decrease client protein expression
to resist inactivation by DPP-4designedto resist inactivation by DPP-4
to the acid environment for h. Pylorimay contributeto the acid environment for h. Pylori
to depletion of mitochondrial DNAledto depletion of mitochondrial DNA
to side effects like eye irritationcan leadto side effects like eye irritation
to resist inactivationdesignedto resist inactivation
excessive bleeding during tattoo treatmentsto causeexcessive bleeding during tattoo treatments
irises ( the colored part of the eyes ) to darkencan causeirises ( the colored part of the eyes ) to darken
more weight loss ( Table ) and gastrointestinal side effects than controls ( nausea , relative risk increase [ RRI ] 192 %causedmore weight loss ( Table ) and gastrointestinal side effects than controls ( nausea , relative risk increase [ RRI ] 192 %
to resist enzymatic degradationdesignedto resist enzymatic degradation
A novel triazole(passive) was discoveredA novel triazole
as substrates and inhibitors of thymidine kinase 1 ( TK1designedas substrates and inhibitors of thymidine kinase 1 ( TK1
A novel traizole(passive) was ... discoveredA novel traizole
to probe and modify enzyme interactionsdesignedto probe and modify enzyme interactions
more weight loss ( Table ) and gastrointestinal side effects than controls ( nausea , relative risk increase [ RRI ] 192 % , 95 % CI 102causedmore weight loss ( Table ) and gastrointestinal side effects than controls ( nausea , relative risk increase [ RRI ] 192 % , 95 % CI 102
to act as competitive alternative substrate inhibitors of virally encoded polymerasesdesignedto act as competitive alternative substrate inhibitors of virally encoded polymerases
AD pathogenic mechanisms through pathways specifically related to the pharmacodynamics of the GLP-1 analogues , even in non - diabetic patientscan influenceAD pathogenic mechanisms through pathways specifically related to the pharmacodynamics of the GLP-1 analogues , even in non - diabetic patients
side effects such as loss of sexual desire , impotence , hot flashes and the development of osteoporosis , which increases the risk of bone fracturescan causeside effects such as loss of sexual desire , impotence , hot flashes and the development of osteoporosis , which increases the risk of bone fractures
increased and prolonged cellular activityprovokeincreased and prolonged cellular activity
for structure - activity relationshipsdesignedfor structure - activity relationships
to the discovery ofleadingto the discovery of
alsomay ... to can ... causealso
to weight loss in patientscan leadto weight loss in patients
red cellscan causered cells
adverse health effectscould causeadverse health effects